In diabetic mice and murine podocyte cell (MPC-5) models, ruxolitinib or wogonin affected autophagy and delayed the progression of DKD through JAK/STAT and Bcl-2-mediated pathways (Chen D. et al., 2021; Liu et al., 2022). This evidence concerns the gene BCL2 and diabetic kidney disease.